循環器ジャーナル72巻3号

2024年07月発行

特集 心房細動—予防・早期発見・治療の進化 Ⅲ.薬物を用いた不整脈治療（特に高齢者や腎機能低下例に対するもの）

SGLT2阻害剤，ARNI，MRAなどのAFへの効果は？

著者： 峰隆直¹

所属機関： ¹兵庫医科大学循環器・腎透析内科

ページ範囲：P.409 - P.414

POINT
●SGLT2阻害剤およびMRAはAFに抑制的に働く．
●ARNIのAFへの効果はACEI/ARBと同等である．
●各薬剤使用時は適応疾患に留意する．

参考文献

1）Okunrintemi V, Mishriky BM, Powell JR, et al. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab 2021 ; 23 : 276-80.

2）Li N, Chelu MG, Birnbaum Y. Dapagliflozin for Atrial Fibrillation. Cardiovasc Drugs Ther 2024 ; 38 : 1-3.

3）Ling AW, Chan CC, Chen SW, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol 2020 ; 19 : 188.

4）Butt JH, Docherty KF, Jhund PS, et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction : insights from DAPA-HF. Eur J Heart Fail 2022 ; 24 : 513-25.

5）Kishima H, Mine T, Fukuhara E, et al. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation. JACC Clin Electrophysiol 2022 ; 8 : 1393-404.

6）Zhao Z, Jiang C, He L, et al. Impact of Sodium-Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes : A Propensity-Score Matching Study and Meta-Analysis. J Am Heart Assoc 2023 ; 12 : e031269.

7）Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010 ; 55 : 2299-307.

8）Wang R, Ye H, Ma L, et al. Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cardiovasc Med 2022 ; 9 : 890481.

9）Liu X, Liu H, Wang L, et al. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure : A systematic review and meta-analysis of randomized controlled trials. PLoS One 2022 ; 17 : e0263131.

10）Mohammad Z, Ahmad J, Sultan A, et al. Effect of sacubitril-valsartan on the incidence of atrial fibrillation : A meta-analysis. J Cardiovasc Electrophysiol 2023 ; 34 : 1037-42.

11）Yang L, Zhang M, Hao Z, et al. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients. ESC Heart Fail 2022 ; 9 : 2428-34.

12）Mayyas F, Alzoubi KH, Van Wagoner DR, et al. Impact of aldosterone antagonists on the substrate for atrial fibrillation : aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol 2013 ; 168 : 5135-42.

13）Neefs J, van den Berg NW, Limpens J, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation : A Systematic Review and Meta-Analysis. Int J Cardiol 2017 ; 231 : 155-61.

14）Lavall D, Jacobs N, Mahfoud F, et al. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem Pharmacol 2019 ; 168 : 173-83.

15）Filippatos G, Bakris GL, Pitt B, et al. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol 2021 ; 78 : 142-52.

16）Zhang Y, Wang J, Jiang L, et al. Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr 2022 ; 14 : 156.